Signal recognition antibody-positive myopathy and response to intravenous immunoglobulin G (IVIG)

Journal of Clinical Rheumatology

Volumn 19, Issue 4, 2013, Pages 214-217

  Garcia Rosell, Melinda ^a,b   Moore, Suzanne ^a,b   Pattanaik, Debendra ^a,b   Menon, Yamini ^a   Bertorini, Tulio ^c   Carbone, Laura ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Wesley Neurology Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD45 ANTIGEN; CREATINE KINASE; IMMUNOGLOBULIN; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; SIGNAL RECOGNITION PARTICLE;

ADULT; ARTICLE; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DISEASE COURSE; DRUG DOSE REDUCTION; FOLLOW UP; HUMAN; IMMUNOASSAY; MALE; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYOPATHY; MYOSITIS; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AUTOANTIBODIES; CREATINE KINASE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; MUSCULAR DISEASES; SIGNAL RECOGNITION PARTICLE;

EID: 84880075766     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0b013e31828e6442     Document Type: Article

References (16)

1. Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum. 1990;33:1361-1370.
2. Hengstman GJD, ter Laak HJ, Vree Egberts WTM, et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis. 2006;65:1635-1638.
3. Kao AH, Lacomis D, Lucas M, et al. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum. 2004;50:209-215.
4. Compston A. Aids to the investigation of peripheral nerve injuries. Medical Research Council: Nerve Injuries Research Committee. His Majesty's Stationery Office: 1942; pp. 48 (iii) and 74 figures and diagrams; with aids to the examination of the peripheral nervous system. By Michael O'Brien for the Guarantors of Brain.
5. Saunders Elsevier: 2010; pp. [8] 64 and 94 Figures. Brain. 2010;133:2838-2844.
6. Cherin P, Pelletier S, Teizeira A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum. 2002;46:467-474.
7. Valiyil R, Casciola-Rosen L, Hong G, et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res. 2010;62:1328-1334.
8. Arlet J-B, Dimitri D, Pagnoux C, et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord. 2006;16:334-336.
9. Whelan BR, Isenberg DA. Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion. Rheumatology. 2009;48:594-595.
10. Rituxan [package insert]. South San Francisco, CA: Biogen Idec Inc and Genentech USA; 2011.
11. Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, the Netherlands. Neuromuscul Disord. 2004;14:337-345.
12. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;362:971-982.
13. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971-982.
14. Benveniste O, Drouot L, Jouen F, et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum. 2011;63:1961-1971.
15. Dalakas MC. Pathophysiology of inflammatory and autoimmune myopathies. Presse Med. 2011;40:e237-e247.
16. Quick A, Tandan R. Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease. Curr Rheumatol Rep. 2011;13:192-198.